Cadila Healthcare v Cadila Pharma: Pharma Trademark Law

Supreme Court of India | March 26, 2001 | AIR 2001 SC 1952 | (2001) 5 SCC 73 B.N. Kirpal, Doraswamy Raju & British Kumar, JJ.

Background

Both the appellant (Cadila Healthcare Limited) and the respondent (Cadila Pharmaceuticals Limited) were successor companies that had acquired the assets and business of the erstwhile Cadila Group following its corporate restructuring under Sections 391 and 394 of the Companies Act. The restructuring scheme specifically permitted both companies to use the name “Cadila” as part of their corporate names.

The dispute arose from the appellant’s allegation that the respondent’s drug “Falcitab” was deceptively similar to the appellant’s drug “Falcigo.” Falcigo, containing Artesunate, was introduced by the appellant for the treatment of cerebral malaria (Falciparum malaria) a serious, potentially fatal disease. The appellant had applied for trademark registration in August 1996 and received Drug Controller approval in October 1996 to market Falcigo across India. In April 1997, the respondent obtained Drug Controller permission to manufacture a drug containing Mefloquine Hydrochloride also used for treatment of Falciparum malaria and began marketing it as “Falcitab.” Critically, both drugs were Schedule L drugs, sold only to hospitals and clinics and not over the counter. Both were drugs of last resort for the same disease but with entirely different compositions and potential side effects.

The appellant filed suit in the District Court, Vadodara seeking injunction. The trial court dismissed the interim injunction application, finding no likelihood of confusion given that the drugs were sold only to hospitals and institutions. The High Court upheld this dismissal. The appellant appealed to the Supreme Court by Special Leave.

The Supreme Court declined to interfere with the concurrent orders refusing injunction, primarily because contested questions of fact required evidence at trial, and directed expeditious disposal of the suit. However, the court used the occasion to comprehensively lay down the legal principles governing deceptive similarity in trademark cases particularly for pharmaceutical products — and expressly disapproved a recent Supreme Court decision (S.M. Dyechem Ltd. v. Cadbury (India) Ltd.) which had diverged from established precedent.

Issues for Determination

What are the applicable tests and principles for determining deceptive similarity between competing trademarks in passing off actions, particularly in the context of pharmaceutical and medicinal products?
Whether the fact that a drug is a Schedule L drug sold only to hospitals and clinics (not over the counter) is by itself a sufficient answer to a claim of passing off based on confusingly similar marks.
Whether the decision in S.M. Dyechem Ltd. v. Cadbury (India) Ltd. which had emphasised differences in essential features over similarities and phonetic resemblance correctly stated the law.
What standard of care is appropriate when assessing confusion in the context of medicinal products, particularly drugs of last resort?

Key Holdings of the Court

Stricter standard applies to pharmaceutical trademarks: Public interest demands heightened judicial scrutiny of trademark similarity in the case of medicinal products. Confusion between drugs — especially those treating the same disease but with different compositions can have disastrous health consequences, including fatality. A lesser quantum of proof of confusing similarity is required for medicinal products than for ordinary consumer goods.
Prescription-only or hospital-only sale does not immunise against confusion: The fact that a drug is a Schedule L drug sold only to hospitals and institutions does not eliminate the possibility of confusion. Physicians, pharmacists, and hospital staff are human and not immune to error particularly given the linguistic diversity, urban-rural divide, and pressures of medical practice in India. Prescriptions may be telephoned or handwritten in illegible script, enhancing the risk.
S.M. Dyechem overruled on the law: The court expressly held that the S.M. Dyechem decision, which had emphasised dissimilarities in essential features over phonetic similarity and applied an English standard that presupposed a literate, discerning consumer, did not correctly state Indian trademark law. The standard established in Amritdhara the unwary purchaser of average intelligence and imperfect recollection remains the binding test.
Similarity, not dissimilarity, is the focus: In line with the consistent line of Supreme Court authority from National Sewing Thread, Corn Products, Amritdhara, Durga Dutt Sharma, and Hoffmann-La Roche, the relevant inquiry is whether the marks are similar enough to likely cause confusion — not whether they can be distinguished upon careful side-by-side comparison.
Comprehensive multi-factor test formulated: The court laid down seven factors to be considered in determining deceptive similarity for unregistered marks in a passing off action.
Regulatory recommendation made: Courts should encourage drug-licensing authorities to require applicants for new drug brand names to submit trademark search reports from the Trade Marks Office, to prevent confusingly similar names from receiving Drug Controller approval in the first instance.

Statutory Provisions Involved

Section 27(1) and (2), Trade and Merchandise Marks Act, 1958 Bars proceedings for infringement of unregistered marks but preserves the common law passing off action.
Section 28, Trade and Merchandise Marks Act, 1958 Confers on the registered proprietor the exclusive right to use the mark and seek relief for infringement.
Section 17-B, Drugs and Cosmetics Act, 1940 Defines a “spurious drug” to include any drug that imitates or resembles another drug in a manner likely to deceive; the court invoked this to support stricter protection for pharmaceutical marks.
Sections 391 and 394, Companies Act, 1956 Schemes of compromise and arrangement; relevant to the background of the Cadila Group restructuring.

Reasoning of the Court

On the inadequacy of the English consumer standard in India: The court emphasised that English case law on trademark confusion was developed in the context of a high-literacy, English-speaking society where consumers were accustomed to the script and language of the marks. India presents an entirely different reality a large percentage of the population is illiterate, there is no single common language, and many consumers have no familiarity with English or the script in which a mark is written. English principles on dissimilarity of marks, or the assumption that consumers know the distinguishing characteristics of the products they buy, cannot be uncritically transplanted to India.

On the S.M. Dyechem decision: The court identified two specific errors in Dyechem: first, its emphasis on differences in essential features over phonetic similarity, and second, its citation of Lord Romer’s observations in Payton & Co. v. Snelling, Lampard & Co. to the effect that courts should focus on the customer who “knows the distinguishing characteristics” of the plaintiff’s goods. Both positions were held to be contrary to the Supreme Court’s binding precedents in Amritdhara, Corn Products, Durga Dutt Sharma, and Hoffmann-La Roche.

On heightened protection for pharmaceutical marks: Drawing extensively from American jurisprudence including decisions of the TTAB, the Second Circuit Court of Appeals, and McCarthy on Trade Marks the court held that the risk of physical harm from confusion between medicinal products justifies a stricter standard of trademark protection. In a passing off context, if there is any real possibility of confusion between two pharmaceutical products, particularly those treating the same disease with different and potentially contraindicated compositions, public policy demands that the use of the confusingly similar mark be restrained.

On the multi-factor test: The seven factors articulated by the court reflect a contextual, holistic approach to deceptive similarity for unregistered marks: (a) nature of the marks, (b) degree of resemblance phonetically and visually, (c) nature of the goods, (d) similarity in character and performance of the goods, (e) class of purchasers and their education, intelligence, and care in purchasing, (f) mode of purchasing or ordering, and (g) any other relevant surrounding circumstances. The court emphasised that the weight to be given to each factor varies from case to case.

Doctrinal Significance

1. The definitive Indian pharmaceutical trademark standard: This judgment is the foundational authority for the proposition that trademark law, in the context of medicinal and pharmaceutical products, must be applied with a heightened standard of strictness. Confusion between medicines can be life-threatening, and courts must therefore require a lesser degree of proof of confusing similarity than would be needed for ordinary consumer products.

2. The “unwary purchaser” standard reaffirmed and contextualised for India: The court firmly reaffirmed Amritdhara‘s standard and explicitly refused to adopt the more demanding English standard that presupposes a literate, discerning consumer. The Indian standard must account for illiteracy, linguistic diversity, and the conditions of medical purchasing in rural and urban India alike.

3. Overruling of S.M. Dyechem similarity over dissimilarity: By overruling Dyechem, the judgment authoritatively settled that in Indian passing off law, the focus must be on similarities rather than dissimilarities, and that phonetic resemblance cannot be subordinated to visual differences in letter-forms or stylisation.

4. Prescription/institutional sale not a safe harbour from confusion claims: The court’s holding that Schedule L or prescription-only status does not insulate a drug from passing off claims is highly significant. It recognises that trained professionals doctors, pharmacists, hospital staff can make mistakes, particularly in high-pressure situations, and that the consequences of such mistakes with drugs are irreversible.

5. The seven-factor deceptive similarity test: The structured multi-factor framework articulated by the court has become the standard analytical template for passing off cases involving unregistered marks in India cited routinely by courts at all levels in pharmaceutical, FMCG, and other trademark disputes.

6. Judicial-regulatory interface drug authority oversight recommended: The court’s direction that drug-licensing authorities should require trademark search reports before approving new brand names represents a rare instance of the Supreme Court using a trademark case to recommend systemic regulatory reform at the intersection of trademark law and pharmaceutical regulation.